This was demonstrated by the substantial upregulation of markers typically associated with the mesenchymal phenotype, including fibronectin, vimentin, and N-cadherin, coupled with the loss of epithelial cell contacts mediated by the junction protein E-cadherin in tumor cells resistant to erlotinib. Here, CDH2 is linked to neoplasm.